Palonosetron in pediatric patients: A single-center, retrospective evaluation of policy and clinical practice guideline discordance.

IF 1 4区 医学 Q4 ONCOLOGY
Journal of Oncology Pharmacy Practice Pub Date : 2025-03-01 Epub Date: 2024-02-29 DOI:10.1177/10781552241233489
Meredith Ames, Priya Patel, L Lee Dupuis, Alicia Koo
{"title":"Palonosetron in pediatric patients: A single-center, retrospective evaluation of policy and clinical practice guideline discordance.","authors":"Meredith Ames, Priya Patel, L Lee Dupuis, Alicia Koo","doi":"10.1177/10781552241233489","DOIUrl":null,"url":null,"abstract":"<p><p>IntroductionClinical practice guidelines (CPGs) recommending palonosetron for the prevention and management of chemotherapy-induced nausea and vomiting (CINV) were adapted for use at our institution. Palonosetron was restricted for use in patients experiencing breakthrough CINV and receiving highly emetogenic chemotherapy (HEC) or undergoing stem cell transplant conditioning and in patients with refractory CINV receiving HEC. Given the significant cost of palonosetron, we aimed to determine the proportion of chemotherapy blocks where palonosetron use was discordant with the institutional policy or source CPG.MethodsA retrospective review of the health records of patients who received palonosetron between 1 July 2019 and 30 June 2020 was undertaken. Details of palonosetron use, antiemetic regimen and the date and time of each vomit during the acute and delayed phases were collected for each chemotherapy block where palonosetron was given. Discordance with the institutional policy and the source CPG was determined by assessing the indication for palonosetron and the dose. In the subset of chemotherapy blocks where information regarding vomiting episodes was available, the extent of acute phase chemotherapy-induced vomiting (CIV) control was reported.ResultsFour hundred thirty-eight chemotherapy blocks, representing 122 patients (mean age 9 years), receiving 595 palonosetron doses were included. Palonosetron use was discordant with institutional policy during most (72%; 314/438) of the chemotherapy blocks analyzed. However, palonosetron use was concordant with the source CPG during most chemotherapy blocks (74%; 326/438). Complete CIV control during the acute phase was observed in 66% (195/295) of chemotherapy blocks where palonosetron was given, irrespective of concomitant antiemetics administered.ConclusionThe majority of palonosetron use at our institution was discordant with institutional policy, but concordant with the source CPG. Our institutional policy has since been updated to be more aligned with the source CPG.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"251-255"},"PeriodicalIF":1.0000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11898370/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Oncology Pharmacy Practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/10781552241233489","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/2/29 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

IntroductionClinical practice guidelines (CPGs) recommending palonosetron for the prevention and management of chemotherapy-induced nausea and vomiting (CINV) were adapted for use at our institution. Palonosetron was restricted for use in patients experiencing breakthrough CINV and receiving highly emetogenic chemotherapy (HEC) or undergoing stem cell transplant conditioning and in patients with refractory CINV receiving HEC. Given the significant cost of palonosetron, we aimed to determine the proportion of chemotherapy blocks where palonosetron use was discordant with the institutional policy or source CPG.MethodsA retrospective review of the health records of patients who received palonosetron between 1 July 2019 and 30 June 2020 was undertaken. Details of palonosetron use, antiemetic regimen and the date and time of each vomit during the acute and delayed phases were collected for each chemotherapy block where palonosetron was given. Discordance with the institutional policy and the source CPG was determined by assessing the indication for palonosetron and the dose. In the subset of chemotherapy blocks where information regarding vomiting episodes was available, the extent of acute phase chemotherapy-induced vomiting (CIV) control was reported.ResultsFour hundred thirty-eight chemotherapy blocks, representing 122 patients (mean age 9 years), receiving 595 palonosetron doses were included. Palonosetron use was discordant with institutional policy during most (72%; 314/438) of the chemotherapy blocks analyzed. However, palonosetron use was concordant with the source CPG during most chemotherapy blocks (74%; 326/438). Complete CIV control during the acute phase was observed in 66% (195/295) of chemotherapy blocks where palonosetron was given, irrespective of concomitant antiemetics administered.ConclusionThe majority of palonosetron use at our institution was discordant with institutional policy, but concordant with the source CPG. Our institutional policy has since been updated to be more aligned with the source CPG.

帕洛诺司琼在儿科患者中的应用:对政策与临床实践指南不一致的单中心回顾性评估。
简介:临床实践指南(CPGs)推荐帕洛诺司琼用于预防和治疗化疗引起的恶心和呕吐(CINV),我院对该指南进行了调整。帕洛诺司琼仅限用于出现突破性CINV、接受高致吐性化疗(HEC)或接受干细胞移植调理的患者,以及接受HEC的难治性CINV患者。鉴于帕洛诺司琼的成本高昂,我们旨在确定帕洛诺司琼的使用与机构政策或来源 CPG 不一致的化疗区的比例:我们对 2019 年 7 月 1 日至 2020 年 6 月 30 日期间接受帕洛诺司琼治疗的患者的健康记录进行了回顾性审查。收集了接受帕洛诺司琼治疗的每个化疗区的帕洛诺司琼使用详情、止吐方案以及急性期和延迟期每次呕吐的日期和时间。通过评估帕洛诺司琼的适应症和剂量,确定是否与机构政策和来源 CPG 不一致。在有呕吐发作相关信息的化疗区块中,报告了急性期化疗诱发呕吐(CIV)的控制程度:结果:共纳入 438 个化疗组,代表 122 名患者(平均年龄为 9 岁),接受了 595 次帕洛诺司琼治疗。在分析的大部分化疗区块中(72%;314/438),帕洛诺司琼的使用与机构政策不符。不过,在大多数化疗区块中,帕洛诺司琼的使用与来源 CPG 一致(74%;326/438)。在使用帕洛诺司琼的化疗区块中,66%(195/295)的化疗区块在急性期完全控制了CIV,与同时使用的止吐药无关:结论:我院大多数帕洛诺司琼的使用与机构政策不符,但与来源 CPG 一致。我们的机构政策已进行了更新,使其与源 CPG 更加一致。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.70
自引率
7.70%
发文量
276
期刊介绍: Journal of Oncology Pharmacy Practice is a peer-reviewed scholarly journal dedicated to educating health professionals about providing pharmaceutical care to patients with cancer. It is the official publication of the International Society for Oncology Pharmacy Practitioners (ISOPP). Publishing pertinent case reports and consensus guidelines...
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信